Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves Pfizer’s breast cancer drug Talzenna

The U.S. Food and Drug Administration approved Pfizer Inc.’s Talzenna (talazoparib) for an advanced form of breast cancer.

Read More »

FDA Lifts Partial Clinical Hold for Mersana’s XMT-1522

Mersana Therapeutics Inc. announced that the U.S. Food and Drug Administration lifted the partial clinical hold on the Phase 1 study of the experimental cancer drug XMT-1522.

Read More »

Novartis trial win lifts profile of new breast cancer drug

Novartis’ efforts to tackle an elusive gene mutation behind tough-to-treat breast cancer were rewarded as the Swiss drugmaker said one of its investigational medicines slowed disease progression.

Read More »

Breast Cancer Device Receives FDA Approval

The U.S. Food and Drug Administration approved the first non-radioactive, dual-tracer for sentinel lymph node biopsy.

Read More »

Roche Q2 2018 Financials: “Firing on All Cylinders”

Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.

Read More »

Anti-PD-L1 Immunotherapy Plus Abraxane Significantly Reduced Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer

Celgene Corporation today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival.

Read More »

AstraZeneca wins speedy approvals for cancer drugs in Japan

AstraZeneca won rapid regulatory approval for new uses of two of the company’s important cancer drugs in Japan.

Read More »

Roche ‘highly encouraged’ by Tecentriq results in breast cancer

Roche said a clinical trial showed the Swiss drugmaker’s immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

Read More »

Puma Biotech gets EU panel nod for breast cancer drug

Puma Biotechnology Inc. won a key recommendation from a European Medicines Agency panel on the company’s lead breast cancer drug, five months after the regulator recommended against approving it.

Read More »

Breast cancer drug combo falls short of survival goal

A combination of Pfizer’s breast cancer medicine Ibrance and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom